[go: up one dir, main page]

WO2003032988A1 - Composition pharmaceutique - Google Patents

Composition pharmaceutique Download PDF

Info

Publication number
WO2003032988A1
WO2003032988A1 PCT/JP2002/010707 JP0210707W WO03032988A1 WO 2003032988 A1 WO2003032988 A1 WO 2003032988A1 JP 0210707 W JP0210707 W JP 0210707W WO 03032988 A1 WO03032988 A1 WO 03032988A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogen
pharmaceutical composition
halogeno
general formula
compound represented
Prior art date
Application number
PCT/JP2002/010707
Other languages
English (en)
Japanese (ja)
Inventor
Tomoyuki Shibata
Shinichi Kurakata
Naomi Shimazaki
Original Assignee
Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Company, Limited filed Critical Sankyo Company, Limited
Publication of WO2003032988A1 publication Critical patent/WO2003032988A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne une composition pharmaceutique permettant d'administrer un composé représenté par la formule générale (I) ou analogue ainsi qu'un composé représenté par la formule générale (II), soit simultanément, soit séparément à un intervalle de temps. Dans ces formules, X est un groupe cyclique benzimidazole ; Y1 représente oxygène ou soufre, Z représente un groupe thiazolidinedione ou analogue ; R représente hydrogène, un groupe alkyle en C1-6 ou analogue ; m est un nombre entier compris entre 1 et 5 ; Ra représente bromo ou iodo ; Rb représente hydrogène, halogéno ou analogue ; Rc représente NRKOR1 [où RK représente hydrogène ou analogue ; et R1 représente un groupe cycloalkyle en C3-10 ou analogue] ; et Rd, Re, et Rf représentent indépendamment les uns des autres hydrogène, halogéno ou analogue.
PCT/JP2002/010707 2001-10-17 2002-10-16 Composition pharmaceutique WO2003032988A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001319631 2001-10-17
JP2001-319631 2001-10-17

Publications (1)

Publication Number Publication Date
WO2003032988A1 true WO2003032988A1 (fr) 2003-04-24

Family

ID=19137153

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/010707 WO2003032988A1 (fr) 2001-10-17 2002-10-16 Composition pharmaceutique

Country Status (1)

Country Link
WO (1) WO2003032988A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010070379A1 (fr) * 2008-12-17 2010-06-24 Centre National De La Recherche Scientifique Traitement combiné d'agoniste rxr-ppargamma/d'inhibiteur de facteur de croissance, servant à l'induction de l'apoptose et au traitement du cancer
AU2007213028B2 (en) * 2006-02-09 2010-10-28 Daiichi Sankyo Company, Limited Anti-cancer pharmaceutical composition

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025598A2 (fr) * 1996-12-11 1998-06-18 Dana-Farber Cancer Institute Procedes et compositions pharmaceutiques inhibant la proliferation de cellules tumorales
WO1998037881A1 (fr) * 1997-02-28 1998-09-03 Warner Lambert Company Methode de traitement ou de prevention du choc septique par administration d'un inhibiteur mek
EP1022272A1 (fr) * 1997-10-08 2000-07-26 Sankyo Company Limited Composes heterocycliques condenses substitues
WO2000061581A1 (fr) * 1999-04-07 2000-10-19 Sankyo Company, Limited Derives amine
JP2000351779A (ja) * 1999-04-07 2000-12-19 Sankyo Co Ltd アミン誘導体化合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025598A2 (fr) * 1996-12-11 1998-06-18 Dana-Farber Cancer Institute Procedes et compositions pharmaceutiques inhibant la proliferation de cellules tumorales
WO1998037881A1 (fr) * 1997-02-28 1998-09-03 Warner Lambert Company Methode de traitement ou de prevention du choc septique par administration d'un inhibiteur mek
EP1022272A1 (fr) * 1997-10-08 2000-07-26 Sankyo Company Limited Composes heterocycliques condenses substitues
WO2000061581A1 (fr) * 1999-04-07 2000-10-19 Sankyo Company, Limited Derives amine
JP2000351779A (ja) * 1999-04-07 2000-12-19 Sankyo Co Ltd アミン誘導体化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAMP HEIDI S. ET AL.: "Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 16, 1997, pages 10811 - 10816, XP002961077 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007213028B2 (en) * 2006-02-09 2010-10-28 Daiichi Sankyo Company, Limited Anti-cancer pharmaceutical composition
AU2007213028C1 (en) * 2006-02-09 2011-05-19 Daiichi Sankyo Company, Limited Anti-cancer pharmaceutical composition
US8263631B2 (en) 2006-02-09 2012-09-11 Daiichi Sankyo Company, Limited Anti-cancer pharmaceutical compositions and methods for treating patients with cancer
WO2010070379A1 (fr) * 2008-12-17 2010-06-24 Centre National De La Recherche Scientifique Traitement combiné d'agoniste rxr-ppargamma/d'inhibiteur de facteur de croissance, servant à l'induction de l'apoptose et au traitement du cancer

Similar Documents

Publication Publication Date Title
CA2477839A1 (fr) Azote contenant des composes heterocycliques et medicaments ainsi constitues
WO2003033493A1 (fr) Activateur du recepteur $g(d) active par le proliferateur de peroxisome
MY137944A (en) Specific glucocorticoid compounds having anti-inflammatory activity
DE60218048D1 (de) Thiophenverbindungen als arzneimittel
EP0894797A4 (fr) Nouveaux derives d'amide et intermediaires utilises pour leur synthese
EP1380562A4 (fr) D riv de l'acide carboxylique et son sel
EP1510516A4 (fr) Compose de pyrazole et composition medicinale le contenant
EP1780209A4 (fr) Compose de type ester d'oxime et initiateur de photopolymerisation contenant un compose de ce type
WO2004000820A3 (fr) Monocycles aromatiques utilises comme modulateurs de la kinase
EP1396493A4 (fr) Composes heterocycliques
CA2398620A1 (fr) Nouveaux derives de pyrazine ou leurs sels, compositions pharmaceutiques contenant ces derives ou leurs sels et intermediaires utilises dans leur preparation
NO20040881L (no) Orale antidiabetes midler.
EP1284266A4 (fr) Nouveaux derives indoliques presentant des activites inhibitrices de chymase et leur procede de preparation
WO2003059907A1 (fr) Composes heterocycliques azotes : procede de preparation et d'utilisation
WO2004099145A3 (fr) Derives cycliques a substitution phenyle
WO2001012202A3 (fr) Utilisation d'agents chimiques chelatants comme agents de neutralisation du blocage neuromusculaire provoque par des medicaments
PL370362A1 (en) 6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
CA2226886A1 (fr) Derives d'aminolactames n-(4-substitue-benzyl)-2
WO2003033506A1 (fr) Derive d'acide d'aminoborane et medicament inhibiteur de proteasomes le contenant
WO2003031414A1 (fr) Nouveau compose heterocyclique et agent anti-inflammatoire
EP1813270A4 (fr) Inhibiteurs des proteines de la famille hsp90
WO2003032988A1 (fr) Composition pharmaceutique
EP1391452A4 (fr) Derive de 4-hydroxypiperidine a activite analgesique
IL145449A0 (en) Processes for preparing pesticidal intermediates
WO2003018591A1 (fr) Derives d'acide b pseudo-lariques, preparation et compositions pharmaceutiques correspondantes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP